



Excipients:

Powder: α,α -Trehalose dihydrate, Poloxamer 407, human serum albumin, potassium dihydrogen phosphate, disodium hydrogen phosphate, potassium chloride, sodium chloride.

Solvent: sodium chloride, water for injections.

This product contains trace quantities of bovine content.

After reconstitution, one dose (0.5 mL) contains:

Dengue virus serotype 1 (live, attenuated)*: $\geq 3.3 \log_{10}$ Plaque-forming units (PFU)/dose

Dengue virus serotype 2 (live, attenuated): $\geq 2.7 \log_{10}$ PFU/dose

Dengue virus serotype 3 (live, attenuated)*: $\geq 4.0 \log_{10}$ PFU/dose

Dengue virus serotype 4 (live, attenuated)*: $\geq 4.5 \log_{10}$ PFU/dose

*Genes of serotype-specific surface proteins engineered into dengue type 2 backbone

Read the package leaflet before use and for reconstitution instructions.

Subcutaneous use after reconstitution.

Reconstitute Qdenga® with the solvent provided.

Store in a refrigerator (2°C-8°C). Do not freeze. Store in the original package.

Keep out of the sight and reach of children.

Jauhi dari kanak-kanak

Product registration holder:

Takeda Malaysia Sdn Bhd

Unit TB-L13-1, Level 13, Tower B, Plaza 33, No. 1, Jalan
Kemajuan, Seksyen 13, 46200 Petaling Jaya, Selangor

MYS 6xxxxxx-01



MALXXXXXXXXXAZ
Controlled Medicine/ Ubat Terkawal

Lot
MAN
EXP

Manufacturer:
IDT Biologika GmbH
Am Pharmapark, 06861 Dessau-Rosslau, Germany
Batch release site:
Takeda GmbH
Robert-Bosch-Strasse 8, 78224 Singen, Germany



Qdenga®

powder and solvent for solution for injection
in pre-filled syringe
Dengue tetravalent vaccine (live, attenuated)

5 vials: powder
5 pre-filled syringes: solvent

5 x 1 dose (0.5 mL)



0.5 ml



Powder and solvent for solution for injection in pre-filled syringe
Dengue tetravalent vaccine (live, attenuated)

7